Spero Therapeutics (SPRO) Receivables (2022 - 2026)
Spero Therapeutics' (SPRO) quarterly Receivables came in at $44000.0 in Q1 2026, down 99.79% YoY from $21.2 million in Q1 2025, and down 99.82% on a QoQ basis from $23.8 million in Q4 2025.
Spero Therapeutics (SPRO) Receivables (2022 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 5 years of Receivables data on file, last reported at $44000.0 in Q1 2026.
- Quarterly Receivables fell 99.79% year-over-year to $44000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $44000.0 (down 99.79% YoY) and the FY2025 annual result came in at $22.3 million, down 57.5% from the prior year.
- Receivables slipped to $44000.0 in Q1 2026, from $23.8 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $55.5 million in Q2 2024 to a low of $44000.0 in Q1 2026.
- A 5-year average of $30.5 million and a median of $26.9 million in 2025 frame the typical range for Receivables.
- Annual changes were most pronounced in 2023 — Receivables surged 36318.32% — and 2026, when it tumbled 99.79%.
- Tracing SPRO's Receivables over 5 years: stood at $131000.0 in 2022, then surged by 36318.32% to $47.7 million in 2023, then increased by 4.34% to $49.8 million in 2024, then tumbled by 52.2% to $23.8 million in 2025, then tumbled by 99.82% to $44000.0 in 2026.
- The last three Receivables figures came in at $44000.0 (Q1 2026), $23.8 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | - |
| 10 | Spero Therapeutics | 71.59 Mn | 20.82 Mn | - | -19,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19,000.00 |
| Mar 31, 2026 | 44,000.00 |
| Dec 31, 2025 | 23.80 Mn |
| Sep 30, 2025 | 2.46 Mn |
| Jun 30, 2025 | 26.91 Mn |
| Mar 31, 2025 | 21.19 Mn |
| Dec 31, 2024 | 49.78 Mn |
| Sep 30, 2024 | 53.28 Mn |
| Jun 30, 2024 | 55.50 Mn |
| Mar 31, 2024 | 54.22 Mn |
| Dec 31, 2023 | 47.71 Mn |
| Dec 31, 2022 | 131,000.00 |